Impact of left-heart myopathy on mitral valve stenosis assessment and interventional outcomes: an <i>in-silico</i> trial
Virtual patient cohorts suggest that MV intervention reduces MG but may not normalize mLAP in patients with impaired LV and LA function. Persistent myocardial dysfunction may limit both symptomatic and exercise capacity improvement, despite successful intervention. As percutaneous treatment options expand, distinguishing myocardial from valve-driven abnormalities is essential for accurate assessment, patient selection, and optimizing outcomes.
Authors
- Joost Lumens (ORCID: https://orcid.org/0000-0001-8129-7384)
- Philippe B. Bertrand (ORCID: https://orcid.org/0000-0001-6324-6874)
- Timothy W. Churchill (ORCID: https://orcid.org/0000-0002-0215-3049)
- Sebastiaan Dhont (ORCID: https://orcid.org/0000-0002-5615-3191)
- Tammo Delhaas (ORCID: https://orcid.org/0000-0001-6897-9700)
- Frank Timmermans (ORCID: https://orcid.org/0000-0002-9693-6406)
- Tim van Loon (ORCID: https://orcid.org/0009-0009-4187-8948)
- Gitte van den Acker (ORCID: https://orcid.org/0009-0005-6304-4371)
Institutions
- Ghent University Hospital (BE)
- Maastricht University (NL)
- Massachusetts General Hospital (US)
- Ziekenhuis Oost-Limburg (BE)
- Hasselt University (BE)
Publication Details
- Journal
- European Heart Journal - Digital Health
- Published
- 2025-08-18
- DOI
- https://doi.org/10.1093/ehjdh/ztaf097
- Citations
- 1
- Primary Topic
- Cardiac Valve Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Fonds Wetenschappelijk Onderzoek
- Vlaamse regering